 |
The FY2027 President’s Budget Request proposes a cut of nearly $1.8 billion for the National Institute of Allergy and Infectious Diseases (NIAID), roughly a 28% cut from FY2026 levels. Overall, the request includes $41.4 billion for the National Institutes of Health, a reduction of nearly 6 billion or 12% compared to FY2026 levels.
NIAID-funded research has fueled some of the biggest public health success stories in recent decades, such as the transformation of HIV/AIDS from a death sentence to a treatable, chronic condition and the development of treatments, vaccines and diagnostics for RSV, tuberculosis, Ebola, type 1 diabetes, malaria and more. Sustained investment in NIAID is essential to advancing early detection, improving treatment, and strengthening health system preparedness for conditions like sepsis and other infectious threats. NIAID research support has had a major impact on understanding and managing patients with serious allergic diseases including food allergy, asthma and atopic dermatitis, chronic diseases seriously impact millions of Americans. NIAID funding also is important to sustain early and mid-career scientists through early investigator and research awards to foster the next generation of researchers that will move discoveries forward. Cutting the NIAID budget will negatively impact future advancements to address the threats of allergic and infectious diseases.
Friends of NIAID urges Congress to reject this proposed severe cut to NIAID and instead, increase funding for NIAID to $7.15 billion in FY2027 to ensure that the nation is ready to respond to current and future disease threats.